Abstract 19236: No Difference in Composite of Patency and Rutherford Class in Patients Receiving Drug Eluting Stents vs. Bare Metal Stents in Peripheral Vascular Interventions
Background: The presence of peripheral arterial disease (PAD) results in limitation of physical activity due to claudication, and when left untreated, develops into limb ischemia followed by limb loss. The use of drug eluting stents (DES) in peripheral vascular interventions (PVI) has been shown to improve patency over angioplasty (PTA) and bare metal stents (BMS), however this was in a cohort of patients with short lesion lengths. Clinical trials comparing the efficacy of the DES in long lesion lengths are not well described, neither in patency or continued symptom relief at 6 months. Here, we compare the a composite endpoint of patency and Rutherford Class in patients receiving DES.
Methods: 277 patients underwent PVI with either DES or BMS from January 2011 to January 2015 for claudication and/or limb ischemia. The primary end point was patency (either ABI improvement above 0.9 or US velocity <250 m/s) and Rutherford class (Class I to VI) at follow up. A Pearson chi-square analysis and multivariate analysis were used to determine results.
Results: A total of 20 patients underwent DES placement and 257 underwent BMS placement. Baseline differences existed between the two groups, particularly stent length. No difference in patency or Rutherford class was observed after correcting for all baseline differences in a multivariate analysis.
Conclusion: After correcting for stent length and baseline characteristics, no significant differences in patency and Rutherford Class was observed. More data is needed in this real world use of DES as the current clinical trials only define very short lesion length, which defines a small subset of the patients treated in modern day practice.
Author Disclosures: P.M. Meraj: None. R. Doshi: None. P. Vijayaraghavan: None. D. Helfgott: None.
- © 2015 by American Heart Association, Inc.